John Contois, PhD.

John H. Contois, PhD, DABCC, FAACC

John H. Contois, PhD, DABCC, FADLM is a clinical chemist and diagnostics innovator with extensive experience in laboratory medicine, assay development and analytical validation. He is the Founder and President of Sun Diagnostics, a company he established in 2012 to provide novel products for assay validation, quality assurance, and the advancement of clinical testing. Under his leadership, Sun Diagnostics has developed first-of-its-kind interference kits, isoform-independent lipoprotein(a) assays, and specialized reagents to improve diagnostic accuracy.

Dr. Contois also served as Vice President of Laboratory Medicine and Laboratory Director at C2N Diagnostics in St. Louis, Missouri, where he contributed to the development and validation of groundbreaking blood-based biomarkers for Alzheimer’s disease, including the first CLIA plasma tests for amyloid and tau proteins.

Previously, he held leadership roles at Quest Diagnostics, LipoScience, the University of Massachusetts Medical Center, and other laboratories. His early research, particularly in lipidology, established the clinical utility of apolipoprotein B as a risk factor for cardiovascular disease, contributing to its adoption in international clinical practice guidelines.

Dr. Contois has published over 60 peer-reviewed articles and book chapters and has served on the editorial boards of Clinica Chimica Acta, Practical Laboratory Medicine, and the Journal of Clinical Lipidology. He is a Diplomate of the American Board of Clinical Chemistry and a Fellow of the Association for Diagnostics and Laboratory Medicine.